We’re delighted to announce our third agreement this week, this time a collaboration with @argenxglobal.
argenx has built one of biotechnology’s most productive antibody engines. We’ll be putting Chai’s frontier molecular design platform into the hands of their scientists.
It’s been a landmark few days for Chai Discovery. From announcing our $400M Series C funding round and our collaboration with @Novartis, to working with argenx, the pace towards better drug design is faster than ever.
We’re delighted to announce our collaboration with @Novartis.
Building on a year-long technical engagement, we’re expanding our collaboration with Novartis to support broader deployment of our technology across multiple therapeutic programs.
Novartis will gain access to our
We’re delighted to announce a collaboration with @pfizer to accelerate their drug discovery efforts.
Pfizer will deploy our latest frontier AI model Chai-3 and a custom model leveraging Pfizer's proprietary data and tailored to their workflows.
Chai-3 shows step-change
2026 #ForbesAI50
Artificial intelligence has become part of our lives, increasingly core to how we work, search for information and express ideas. In the last year, the startups spearheading this paradigm shift have raised gobs of money from venture firms to build applications
We are scaling fast and hiring for multiple roles across product, engineering, business, and science. If you are a motivated self-starter, please reach out via
There are only a few other areas where AI has the potential to change lives more than the discovery and development of new medicines to improve lives for patients.
We thank @jackdent and @BenjamineYLiu for this discussion about how America needs to continue to lead in biopharma
Pharma Bets Big on AI Platforms with Flurry of New Year Deals
@chaidiscovery, @NOETIK_ai, and #Boltz have entered multi-year pharma partnerships focused on models, not molecules, hinting at AI’s “infrastructure moment”
#biopharma#AI#drugdiscovery
Thank you @LucasRopek1 for this feature in @TechCrunch highlighting our journey at @chaidiscovery.
Grateful to our partners @generalcatalyst and @EliLillyandCo for adding your perspectives on how Chai is helping to unlock medicines that have historically been difficult to drug.
We’re thrilled to announce our collaboration with @EliLillyandCo.
We’ll be deploying Chai’s AI models to power biologics discovery across a broad set of drug programs at Lilly.
This is a major step forward in pharma’s adoption of AI-native R&D.
As part of this work, Chai and Lilly are building a custom foundation model, trained on Lilly’s proprietary data and tailored to their internal discovery efforts.
Seeing a leading pharma organization move quickly to adopt these technologies reinforces our belief that many future drugs will be discovered with AI.
Grateful to the teams on both sides who made this possible. Excited to see the medicines that get created from here.
